Gunderson Capital Management Inc. Purchases 5,343 Shares of Eli Lilly and Company $LLY

Gunderson Capital Management Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 197.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,046 shares of the company’s stock after purchasing an additional 5,343 shares during the period. Eli Lilly and Company makes up approximately 2.3% of Gunderson Capital Management Inc.’s holdings, making the stock its 20th largest holding. Gunderson Capital Management Inc.’s holdings in Eli Lilly and Company were worth $6,139,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter worth approximately $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $31,000. Finally, Bare Financial Services Inc boosted its stake in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 4.1%

LLY opened at $1,107.54 on Thursday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,117.66. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business has a 50 day simple moving average of $1,028.26 and a two-hundred day simple moving average of $856.98. The firm has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 54.18, a PEG ratio of 0.77 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 33.86%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research note on Monday, December 1st. Morgan Stanley boosted their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. Bank of America decreased their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $1,169.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.